Show simple item record

dc.contributor.authorSirima, Sodiomon B
dc.contributor.authorOuedraogo, Alphonse
dc.contributor.authorBarry, Nouhoun
dc.contributor.authorSiribie, Mohamadou
dc.contributor.authorTiono, Alfred
dc.contributor.authorNébié, Issa
dc.contributor.authorKonaté, Amadou
dc.contributor.authorBerges, Gloria Damoaliga
dc.contributor.authorDiarra, Amidou
dc.contributor.authorOuedraogo, Moussa
dc.contributor.authorBougouma, Edith C
dc.contributor.authorSoulama, Issiaka
dc.contributor.authorHema, Alimatou
dc.contributor.authorDatta, Shrimati
dc.contributor.authorLiang, Yuanyuan
dc.contributor.authorRotrosen, Elizabeth T
dc.contributor.authorKathleen Tracy, J
dc.contributor.authorJamka, Leslie P
dc.contributor.authorOshinsky, Jennifer J
dc.contributor.authorPasetti, Marcela F
dc.contributor.authorNeuzil, Kathleen M
dc.contributor.authorLaurens, Matthew B
dc.date.accessioned2021-06-11T12:59:47Z
dc.date.available2021-06-11T12:59:47Z
dc.date.issued2021-06-01
dc.identifier.urihttp://hdl.handle.net/10713/15989
dc.description.abstractObjectives: In 2017, the World Health Organisation (WHO) pre-qualified a single-dose typhoid conjugate vaccine (TCV) and identified TCV co-administration studies as a research priority. We tested co-administration of Typbar TCV® (Bharat Biotech International) with measles-rubella (MR) and yellow fever (YF) vaccines. Methods: We conducted a randomised, double-blind, and controlled, phase 2 trial in Ouagadougou, Burkina Faso. Healthy children aged 9-11 months were randomised 1:1 to receive TCV (Group 1) or control vaccine (inactivated polio vaccine (IPV), Group 2). Vaccines were administered intramuscularly with routine MR and YF vaccines. Safety was assessed by 1) local and systemic reactions on days 0, 3, and 7; 2) unsolicited adverse events within 28 days; and 3) serious adverse events (SAEs) within 6 months after immunisation. Results: We enrolled, randomised, and vaccinated 100 eligible children (49 Group 1 and 51 Group 2). Safety outcomes occurred with similar frequency in both groups: local/solicited reactions (Group 1: 1/49, Group 2: 3/50), systemic/solicited reactions (Group 1: 4/49, Group 2: 9/50), unsolicited adverse events (Group 1: 26/49, Group 2: 33/51), and SAEs (Group 1: 2/49, Group 2: 3/51). TCV conferred robust immunogenicity without interference with MR or YF vaccines. Conclusion: TCV can be safely co-administered with MR and YF vaccines to children at the 9-month vaccination visit.en_US
dc.description.urihttps://doi.org/10.1016/j.ijid.2021.05.061en_US
dc.language.isoenen_US
dc.publisherElsevier Ltd.en_US
dc.relation.ispartofInternational Journal of Infectious Diseases : IJIDen_US
dc.rightsCopyright © 2021. Published by Elsevier Ltd.en_US
dc.subjectBurkina Fasoen_US
dc.subjectTyphoid Feveren_US
dc.subjectYellow fever vaccineen_US
dc.subjectcoadministrationen_US
dc.subjecttyphoid conjugate vaccineen_US
dc.titleSafety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomised controlled phase 2 trialen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ijid.2021.05.061
dc.identifier.pmid34082090
dc.identifier.eissn1878-3511
dc.source.countryCanada


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record